Search

Your search keyword '"Biotechnology industry -- Licensing agreements"' showing total 3,394 results
Start Over Descriptor "Biotechnology industry -- Licensing agreements"
3,394 results on '"Biotechnology industry -- Licensing agreements"'

51. Press Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

Subjects
Novavax Inc. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine [...]

Published
2024

52. Enveric Biosciences Unveils Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids

Subjects
United States. Department of Health and Human Services, Phenols -- Licensing agreements, Biotechnology industry -- Licensing agreements, Cannabinoids -- Methods, Chemotherapy -- Methods, Cancer -- Chemotherapy, Breast cancer -- Methods, Controlled substances -- Methods, Company licensing agreement, General interest, News, opinion and commentary
Abstract

CAMBRIDGE: Enveric Biosciences, Inc, announces that it has signed a non-binding term sheet with an undisclosed biotechnology development and commercialization company to exclusively out-license two patent families of Methods for [...]

Published
2024

53. Yield10 Bioscience finalize global license to advance Camelina technology

Subjects
Biotechnology industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Yield10 Bioscience announced that the Company has exercised its option to finalize an exclusive global, commercial license to advanced omega-3 production technology from U.K.-based Rothamsted Research. In 2020, Yield10 signed [...]

Published
2023

54. Dare Bioscience announces first shipment of XACIATOTM

Subjects
Biotechnology industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Dare Bioscience (DARE) announced the first shipment of XACIATOTM vaginal gel, 2% in connection with the first commercial sale of the product in the United States, triggering a $1.8 million [...]

Published
2023

55. Lexaria Bioscience enters license agreement with SulfoSyn

Subjects
Cash transactions, Biotechnology industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Lexaria Bioscience has granted a new global, exclusive license to use DehydraTECH technology to SulfoSyn. The exclusive license granted to SulfoSyn is for all non-pharmaceutical uses of sulforaphane world-wide, including [...]

Published
2023

56. Everest Medicines collaborates with Kezar Life Sciences to develop and commercialize zetomipzomib in Greater China and other Asian markets

Subjects
Lupus, Biotechnology industry -- Licensing agreements, Drugs -- Licensing agreements, Kidney diseases, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

Everest Medicines, a biopharmaceutical company, announced it has entered into a collaboration and license agreement with Kezar Life Sciences (Kezar), a clinical-stage biotechnology company, to develop and commercialize Kezar's lead [...]

Published
2023

57. PeptiDream inks collaboration and licensing pact with Genentech to discover & develop novel peptide-radioisotope drug conjugates

Subjects
Genentech Inc. -- Licensing agreements, Roche Holding AG -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Peptides, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company, announced a new multi-target collaboration and license agreement with US-based Genentech, a member of the Roche Group, focused on the discovery and [...]

Published
2023

58. ERS Genomics & AlgenScribe enter into CRISPR/Cas9 licensing agreement

Subjects
Biotechnology industry -- Licensing agreements, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

ERS Genomics Limited (ERS), a biotechnology company, has announce a new license agreement with AlgenScribe SAS (AlgenScribe). This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 [...]

Published
2023

59. Doer Bio grants BioNTech license to utilize its innovative discoveries to research, develop, manufacture, and commercialize biotherapeutics against an undisclosed target

Subjects
BioNTech SE -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

Zhejiang Doer Biologics Co., Ltd. (Doer Bio), a clinical stage biopharmaceutical company, announced that it has entered into a license agreement with BioNTech SE. Under the terms of the agreement, [...]

Published
2023

60. Brii Biosciences expands license agreements with VBI Vaccines in hepatitis B virus field

Subjects
Biotechnology industry -- Licensing agreements, Hepatitis B -- Health aspects, Vaccines -- Licensing agreements, Hepatitis B virus -- Health aspects, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

Brii Biosciences Limited, a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, announced that it has entered into license agreements with VBI [...]

Published
2023

61. Dare Bioscience to receive $1.0M in July from Organon under license agreement

Subjects
Biotechnology industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Dare Bioscience (DARE) reaffirmed its commitment to the commercial launch of XACIATO, or clindamycin phosphate, vaginal gel, 2% with collaborator Organon (OGN), and announced that Organon will pay Dare $1.0M [...]

Published
2023

63. Why Enveric Biosciences shares are surging Tuesday?

Subjects
Biotechnology industry -- Licensing agreements, Stocks -- Licensing agreements -- Prices and rates, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Shares of Enveric Biosciences ENVB traded higher after the company signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for pharmaceutical [...]

Published
2024

64. Allogene Therapeutics And Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

Subjects
Allogene Therapeutics Inc. -- Licensing agreements, Genes, Biotechnology, Biotechnology industry -- Licensing agreements, Chemotherapy, Cancer -- Chemotherapy, Company licensing agreement, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO: Allogene Therapeutics, Inc. and Arbor Biotechnologies, Inc. announce a non-exclusive, global gene editing licensing agreement for the use of Arbor's proprietary CRISPR gene-editing technology in Allogene's next-generation [...]

Published
2024

65. Biotechnology Licensing Deals Analysis Reveals Key Trends and Major Agreements from 2019-2024

Subjects
Biotechnology -- Reports, Biotechnology industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - The 'Licensing Deals in Biotechnology 2019-2024' report has been added to ResearchAndMarkets.com's offering. Comprehensive Report Unveils In-Depth Insights into Biopharma Licensing Agreements, Financial Terms, and Contract Documents. The [...]

Published
2024

66. Compugen to Present at the Leerink Partners Global Biopharma Conference 2024

Subjects
AstraZeneca PLC -- Licensing agreements, Compugen Ltd. -- Licensing agreements, Biological products industry -- Licensing agreements, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Viral antibodies, Conferences and conventions, Antibodies, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

HOLON, Israel, Feb. 26, 2024 /PRNewswire/ -- http://www.cgen.com/(NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in [...]

Published
2024

67. Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences

Subjects
Caribou Biosciences Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

DURHAM, N.C. -- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS([R]) platform to develop in vivo gene editing therapies for sophisticated gene edits, [...]

Published
2024

68. Yield10 Bioscience Grants Global License to VISION Bioenergy Oilseeds for Herbicide Tolerant Camelina Cultivated for the Production of Biofuel Feedstock

Subjects
Biomass energy, Biotechnology industry -- Licensing agreements, Company licensing agreement, Petroleum, energy and mining industries
Abstract

(GlobeNewswire) - Yield10 Bioscience, Inc. (Nasdaq:YTEN) (Yield10 or the Company), an agricultural bioscience company, and VISION Bioenergy Oilseeds, LLC (VISION), a U.S. agricultural company focused on commercial production of ultra-low [...]

Published
2024

69. Sidley Represents Sagard Healthcare in Royalty Purchase Agreement with MannKind Corporation for up to US$200 Million

Subjects
Mannkind Corp. -- Licensing agreements, United Therapeutics Corp. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Treprostinil -- Licensing agreements, Drug approval, Pulmonary hypertension, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international, Tyvaso (Medication) -- Licensing agreements
Abstract

Chicago: Sidley Austin has issued the following press release: Sidley represented Sagard Healthcare in purchasing a 1% royalty in net sales of Tyvaso DPI(r) (treprostinil) inhalation powder from MannKind Corporation [...]

Published
2024

70. GSK secures global rights to CureVac's mRNA vaccines in new licensing deal

Subjects
CureVac N.V. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Messenger RNA, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-July 3, 2024-GSK secures global rights to CureVac's mRNA vaccines in new licensing deal (C)2024 M2 COMMUNICATIONS Biopharmaceutical company GSK plc (LSE/NYSE: GSK) and biotech firm CureVac N.V. (Nasdaq: [...]

Published
2024

71. GSK secures global rights to CureVac's mRNA vaccines in new licensing deal

Subjects
CureVac N.V. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Messenger RNA, Company licensing agreement, Business
Abstract

M2 EQUITYBITES-July 3, 2024-GSK secures global rights to CureVac's mRNA vaccines in new licensing deal (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Biopharmaceutical company GSK plc (LSE/NYSE: GSK) and biotech firm CureVac N.V. [...]

Published
2024

72. Circe Bioscience licenses technology to decarbonize industry with microbes developed at Wyss Institute at Harvard University

Subjects
Microorganisms, Biotechnology, Biotechnology industry -- Licensing agreements, Emissions (Pollution), Company licensing agreement, Biotechnology industry, Pharmaceuticals and cosmetics industries, Harvard University
Abstract

2024 MAY 29 (NewsRx) -- By a News Reporter-Staff News Editor at Biotech Week -- The Wyss Institute for Biologically Inspired Engineering at Harvard University announced that Circe, a startup [...]

Published
2024

73. Nona Biosciences signs license agreement with AstraZeneca

Subjects
AstraZeneca PLC -- Licensing agreements, Biotechnology industry -- Licensing agreements, Monoclonal antibodies, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business
Abstract

M2 EQUITYBITES-May 23, 2024-Nona Biosciences signs license agreement with AstraZeneca (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk Nona Biosciences, a US-based global biotechnology company, announced on Wednesday that it has signed a license [...]

Published
2024

74. Nona Biosciences signs license agreement with AstraZeneca

Subjects
AstraZeneca PLC -- Licensing agreements, Biotechnology industry -- Licensing agreements, Monoclonal antibodies, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-May 23, 2024-Nona Biosciences signs license agreement with AstraZeneca (C)2024 M2 COMMUNICATIONS Nona Biosciences, a US-based global biotechnology company, announced on Wednesday that it has signed a license agreement [...]

Published
2024

75. MaxCyte and Legend Biotech sign strategic platform licence agreement

Subjects
MaxCyte Inc. -- Licensing agreements, T cells, Biotechnology, Biotechnology industry -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-May 22, 2024-MaxCyte and Legend Biotech sign strategic platform licence agreement (C)2024 M2 COMMUNICATIONS MaxCyte Inc (Nasdaq: MXCT) (LSE: MXCT), a cell-engineering company, announced on Wednesday that it has [...]

Published
2024

76. MaxCyte and Legend Biotech sign strategic platform licence agreement

Subjects
MaxCyte Inc. -- Licensing agreements, T cells, Biotechnology, Biotechnology industry -- Licensing agreements, Company licensing agreement, Business
Abstract

M2 EQUITYBITES-May 22, 2024-MaxCyte and Legend Biotech sign strategic platform licence agreement (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk MaxCyte Inc (Nasdaq: MXCT) (LSE: MXCT), a cell-engineering company, announced on Wednesday that it [...]

Published
2024

77. Sanofi and Novavax sign co-exclusive licensing agreement

Subjects
Novavax Inc. -- Licensing agreements, Euronext Paris S.A. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Health care industry -- Licensing agreements, Securities industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Health care industry, Securities industry, Company licensing agreement, Business
Abstract

M2 EQUITYBITES-May 10, 2024-Sanofi and Novavax sign co-exclusive licensing agreement (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Novavax Inc (Nasdaq:NVAX) announced [...]

Published
2024

78. Sanofi and Novavax sign co-exclusive licensing agreement

Subjects
Novavax Inc. -- Licensing agreements, Euronext Paris S.A. -- Licensing agreements, Sanofi S.A. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Health care industry -- Licensing agreements, Securities industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Health care industry, Securities industry, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-May 10, 2024-Sanofi and Novavax sign co-exclusive licensing agreement (C)2024 M2 COMMUNICATIONS French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) and US biotechnology company Novavax Inc (Nasdaq:NVAX) announced on [...]

Published
2024

79. MD Anderson and CureVac enter strategic collaboration to develop novel cancer vaccines

Subjects
CureVac N.V. -- Licensing agreements, Medical research, Medicine, Experimental, Biotechnology industry -- Licensing agreements, Antigens, RNA, Cancer vaccines -- Licensing agreements, Company licensing agreement, Business, Health, Health care industry
Abstract

2024 MAY 5 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Letter on the CDC & FDA -- HOUSTON and TUBINGEN, Germany - The University of Texas MD [...]

Published
2024

80. Eterna inks option and license agreement with Lineage Cell Therapeutics to develop iPSC lines for multiple neurology indications

Subjects
Cell Therapeutics Inc. -- Licensing agreements, Intellectual property, Stem cells -- Transplantation, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Intellectual property, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

Eterna Therapeutics Inc., a preclinical-stage biotechnology company announced that it has entered into an exclusive option and license agreement (the 'Agreement') with Lineage Cell Therapeutics, Inc. (Lineage) for the development [...]

Published
2023

81. Herbolea Biotech ink agreement granting Iberfar the rights to utilize its extraction and purification technologies in Portugal

Subjects
Biotechnology, Biotechnology industry -- Licensing agreements, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

Iberfar IndȦstria Farmacêutica S.A (Iberfar), a Portuguese Pharmaceutical Group operating a state-of-the-art manufacturing facility near Lisbon, and Herbolea Biotech SpA (Herbolea), an Italian biotech company that licenses proprietary technologies for [...]

Published
2022

82. MaxCyte to expedite scale-up manufacturing of Wugen's Investigational Allogeneic

Subjects
MaxCyte Inc. -- Licensing agreements, Homeopathy -- Materia medica and therapeutics, Biotechnology industry -- Licensing agreements, Therapeutics -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

ROCKVILLE: MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing [...]

Published
2024

83. GenEdit Reports Multiyear Collaboration and License Agreement with Genentech

Subjects
Roche Holding AG -- Licensing agreements, Biological products industry -- Licensing agreements, Nucleic acids, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

South San Francisco: GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxy(r) platform for tissue-selective delivery, announced a multiyear collaboration and license agreement with Genentech, a member of [...]

Published
2024

84. MaxCyte Sign Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Subjects
MaxCyte Inc. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Immunotherapy, Cancer -- Care and treatment, Company licensing agreement, General interest, News, opinion and commentary
Abstract

ROCKVILLE: MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing [...]

Published
2024

85. GenEdit Announces Multiyear Collaboration and License Agreement with Genentech to Develop Novel Nanoparticles to Deliver Genetic Medicines for Autoimmune Disease

Subjects
Roche Holding AG -- Licensing agreements, Biological products industry -- Licensing agreements, Nucleic acids, Nanoparticles, Biotechnology industry -- Licensing agreements, Drugs -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

SOUTH SAN FRANCISCO, Calif. -- GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxy[R] platform for tissue-selective delivery, today announced a multiyear collaboration and license agreement with Genentech, [...]

Published
2024

86. MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Subjects
Imugene Ltd. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Immunotherapy, Cancer -- Care and treatment, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

ROCKVILLE, Md., and SYDNEY, Australia, Jan. 23, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=ELIYjWa3dgeNHL15M1eCvJRD13zJxqX8b6-lBZKbm-etFeoHSqitcxP5l0ojgZCxA8QOQFPKbZgVjH3lJXfIBw==, (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development [...]

Published
2024

87. ERS Genomics and StemSight Enter into a License Agreement for CRISPR|Cas9

Subjects
Stem cells -- Transplantation, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

DUBLIN: ERS Genomics Limited has announced a non-exclusive CRISPR/Cas9 license agreement with StemSight Oy, a biotechnology company developing stem cell-based therapies for corneal blindness. The agreement grants StemSight access to [...]

Published
2024

88. Biocodex Group Enhances Microbiota Presence Through a Licensing Agreement with My Health, a Belgian Biotech Firm Specialized in Microbiota Solutions

Subjects
Microbiota (Symbiotic organisms), Biotechnology, Biotechnology industry -- Licensing agreements, Dietary supplements -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Paris: Biocodex, a French pharmaceutical group, has signed a licensing agreement with Belgian biotech company My Health to market the DUOSPORE(r) dietary supplement in several countries. My Health, founded in [...]

Published
2024

89. ERS Genomics and StemSight Sign CRISPR/Cas9 License Agreement

Subjects
Blindness, Intellectual property, Stem cells -- Transplantation, Biotechnology industry -- Licensing agreements, Intellectual property, Company licensing agreement, Business, Business, international
Abstract

* License agreement provides StemSight access to CRISPR/Cas9 technology to be applied in development of cell therapies for corneal blindness DUBLIN, Ireland & TAMPERE, Finland -- ERS Genomics Limited ('ERS'), [...]

Published
2024

90. Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

Subjects
Biotechnology industry -- Licensing agreements, Autoimmune diseases, Company licensing agreement, General interest, News, opinion and commentary
Abstract

DURHAM: PRECISION BIOSCIENCES, INC. has issued the following news release: Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS(r) platform to develop in vivo [...]

Published
2024

91. TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases

Subjects
T cells, Biotechnology, Biotechnology industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), 'the Company,' today https://www.globenewswire.com/Tracker?data=Qc49-grK-96P_feYaRa3jnVgOkYlIajaC75UsqBeQPCTIlX5-xCXedqwG52ei5kdO17uH2LVEFb-tVn8uH5lFDrVoZ783ZPAT2RbBElpodapw9dIEp6WMDEe3UjBJbxso2i3mHf6FIOXArE60OOaNQ== with https://www.globenewswire.com/Tracker?data=Ed3rWC9IM0X9fZmWVogaDmrtIe2WGwpoZp_DgY1T7lvYzmWFC4nBXE7h9kjV9kg_wb1uhibX3RlRI1iD9W7PcirSnmZVceVHa1qcKaeqXT0=, Inc. (https://www.globenewswire.com/Tracker?data=fe--j4woavlQQylGpdT75IRwpKLypU69ECsKwI50hu1omti_scT2KOXGTwOKuzpERdF-wJ_6LApUa3onFSbyhg== GS: DTIL) to acquire a worldwide license to Precision's [...]

Published
2024

93. Galapagos join hands with BridGene Biosciences to expand drug discovery in oncology

Subjects
Galapagos N.V. -- Licensing agreements, Drug discovery, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Mechelen: Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. ('Bridgene'), a biotechnology company that uses [...]

Published
2024

94. Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Subjects
Galapagos N.V. -- Licensing agreements, Drug discovery, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

Strategic collaboration and licensing agreement further strengthens Galapagos' growing early-stage pipeline in oncology precision medicine Collaboration leverages Galapagos' expertise in small molecule drug discovery and development with BridGene's innovative discovery [...]

Published
2024

95. Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology

Subjects
Galapagos N.V. -- Licensing agreements, Drug discovery, Biotechnology industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - Strategic collaboration and licensing agreement further strengthens Galapagos' growing early-stage pipeline in oncology precision medicine - Collaboration leverages Galapagos' expertise in small molecule drug [...]

Published
2024

96. MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement

Subjects
Mannkind Corp. -- Licensing agreements, United Therapeutics Corp. -- Licensing agreements, Biotechnology industry -- Licensing agreements, Treprostinil -- Licensing agreements, Drug approval, Pulmonary hypertension, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary, Tyvaso (Medication) -- Licensing agreements
Abstract

WESTLAKE VILLAGE: MannKind Corporation announced that on December 27, 2023 it sold a 1% royalty in net sales of Tyvaso DPI(r) (treprostinil) inhalation powder in exchange for up to $200 [...]

Published
2024

97. Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Subjects
Rate of return, Biotechnology industry -- Licensing agreements, Governmental investigations, Return on investment, Company licensing agreement, Banking, finance and accounting industries
Abstract

(GlobeNewswire) - Dar Bioscience, Inc. (NASDAQ: DARE), a leader in womens health innovation, today announced it has entered into a royalty-backed financing agreement that provides Dar with $5 million at [...]

Published
2023

98. Dare Bioscience Secures $12 Million in Royalty-backed Investment Structure

Subjects
Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

SAN DIEGO: Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced it has entered into a royalty-backed financing agreement that provides Dare with $5 million at [...]

Published
2023

99. Dare Bioscience Secures $12 million in Royalty-backed Investment Structure

Subjects
Rate of return, Biotechnology industry -- Licensing agreements, Governmental investigations, Return on investment, Company licensing agreement, Banking, finance and accounting industries, Business
Abstract

SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Dare Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced it has entered into a royalty-backed financing agreement that [...]

Published
2023

100. Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology

Subjects
Compugen Ltd. -- Licensing agreements, Protein binding, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

HOLON: Compugen Ltd has issued the following news release: Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results